体外光分离置换疗法在白血病型皮肤T细胞淋巴瘤中诱导免疫原性细胞死亡并激活树突状细胞
该研究通过体外实验和接受ECP治疗的白血病型CTCL患者白细胞离体实验,发现ECP可诱导免疫原性细胞死亡(ICD)标志物释放,且CD4+CD26-恶性T细胞更易发生ICD,ECP处理的CD4+ T细胞被树突状细胞吞噬并依赖ICD信号,提示ECP增强靶向免疫应答。
要点
- ECP可诱导白血病型CTCL患者恶性T细胞发生免疫原性细胞死亡。
- CD4+CD26- T细胞对ECP诱导的ICD更敏感,提示靶向肿瘤细胞。
- ECP处理的CD4+ T细胞被树突状细胞吞噬,该过程依赖ICD信号。
核心结论
- ECP在白血病型CTCL中诱导恶性T细胞发生ICD,并促进树突状细胞活化,从而增强靶向免疫应答。
研究设计与样本
- 研究采用健康供者外周血单个核细胞的体外实验和接受ECP治疗的白血病型CTCL患者白细胞的离体实验。
- 通过流式细胞术、酶联免疫吸附试验和定量聚合酶链反应评估细胞活力、凋亡及ICD标志物。
- 采用吞噬实验评估ECP处理的CD4+ T细胞对树突状细胞的活化作用。
主要发现
- ECP处理的健康PBMC和白血病型CTCL患者白细胞均显著诱导ICD标志物,包括ATP释放、HMGB1分泌和钙网蛋白表面暴露。
- 在白血病型CTCL患者中,钙网蛋白暴露主要见于CD4+CD26- T细胞,提示恶性T细胞对ICD更敏感。
- ECP处理的CD4+ T细胞被树突状细胞吞噬,且该过程依赖ICD信号。
关键数值与推荐
- ICD标志物包括ATP释放、HMGB1分泌和钙网蛋白表面暴露。
- 钙网蛋白暴露主要存在于CD4+CD26- T细胞。
临床怎么用
- ECP通过诱导ICD和树突状细胞活化增强抗肿瘤免疫,支持其在白血病型CTCL中的应用。
- CD4+CD26- T细胞对ICD的高敏感性可作为ECP靶向恶性T细胞的潜在生物标志物。
局限性
- 研究为体外和离体实验,尚未在体内验证ECP诱导ICD的临床免疫效应。
- 样本来源和数量未在摘要中明确报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite novel therapeutic options, the long-term management of cutaneous T-cell lymphoma (CTCL) remains challenging. Extracorporeal photopheresis (ECP) is an immunomodulating photochemotherapy associated with higher overall survival when used for the treatment of leukaemic forms of CTCL. Its exact mode of action has not been fully elucidated. Immunogenic cell death (ICD) is pivotal in cancer immunotherapy, marked by the release of damage-associated molecular patterns that enhance dendritic cell (DC) maturation and cytotoxic T-lymphocyte responses. OBJECTIVES: To explore ICD in patients with leukaemic forms of CTCL during ECP and its effect on DC activation. METHODS: We conducted in vitro studies with peripheral blood mononuclear cells (PBMCs) from healthy donors and ex vivo experiments with white blood cells (WBCs) from patients with leukaemic forms of CTCL undergoing ECP. We assessed cell viability, apoptosis and ICD markers [ATP, high mobility group box 1 protein (HMGB1), calreticulin] using flow cytometry, enzyme-linked immunosorbent assay and quantitative polymerase chain reaction. Engulfment assays evaluated DC activation by ECP-treated CD4+ T cells. RESULTS: ECP-treated healthy PBMCs and WBCs from patients with leukaemic forms of CTCL showed a significant induction of ICD hallmarks, including ATP release, HMGB1 secretion and calreticulin surface exposure. In patients with leukaemic forms of CTCL, calreticulin exposure was mainly present in CD4+CD26- T cells, indicating greater ICD susceptibility of malignant T cells. ECP-treated CD4+ T cells were phagocytosed by DCs, a process that was found to be dependent on ICD signals. CONCLUSIONS: ECP induces ICD in malignant T cells and, to a lesser extent, in healthy T cells, facilitates DC activation. These findings suggest that ECP enhances targeted immune responses against malignant T cells in leukaemic forms of CTCL, offering new insights into its therapeutic mechanisms and potential applications in cancer immunotherapy. Cutaneous T-cell lymphoma (‘CTCL’ for short) is a type of skin cancer that can also affect the blood. ‘Extracorporeal photopheresis’ (or ‘ECP’ for short) is used to treat people with a form of CTCL known as ‘leukaemic CTCL’. ECP takes white blood cells from a patient and treats them with a special light-sensitive drug. The cells are then exposed to ultraviolet A light (UVA) before being returned into the patient. While ECP is effective and safe, scientists still do not fully understand how it works. We investigated a process called ‘immunogenic cell death’ in patients with leukaemic forms of CTCL during ECP. We also looked at its effect on the activation of dendritic cells, a type of cell found in the immune system. We found that ECP triggers immunogenic cell death in patients with CTCL. This means that as the treated cancer cells die, they send signals to the immune system. This helps the immune system to recognize and attack more cancer cells. We also found that a specific type of cancerous T cell (called CD4+CD26– T cells) are very sensitive to this process. This suggests that ECP specifically targets tumour cells in patients with leukaemic CTCL, making it a promising treatment. In conclusion, our research shows how ECP helps the immune system fight CTCL. Future studies should focus on improving ECP treatment to make it even more effective for CTCL and possibly other T-cell cancers.
引用
- Lackner A, Burner T, Huber M, et al. Evidence of immunogenic cell death (ICD) and ICD-dependent dendritic cell activation induced by extracorporeal photopheresis in patients with leukaemic forms of cutaneous T-cell lymphoma. Br J Dermatol. 2025. PMID: 40112181. doi:10.1093/bjd/ljaf102
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。